Abstract
It is easy, in this modern age, to forget the fear and trepidation surrounding infectious disease that has ruled humanity from antiquity. Diseases that were epidemic such as flea-borne bubonic plague, as well as water-borne ailments including typhoid, mosquito-borne malaria, viral-borne small pox and polio were highly feared. Infections that occurred sporadically as endemic in nature included rabies, lockjaw, botulism, and anthrax and were terrifying prospects that could arise from relatively minor scrapes (a dog bite, stepping on a nail, eating contaminated food, or from breathing spores, respectively). Improved sanitation practices allowed people to avoid contracting many illnesses and, eventually, vaccination greatly reduced the worst microbial and viral diseases. By the turn of the twentieth century, the public began to expect that the federal government should provide regulation of food and drugs and otherwise contribute to the public welfare via legislation. In a reactionary manner, these regulatory efforts proceeded in fits and starts, usually as a counter to specific tragedies.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Notes
- 1.
Refers to Jung’s question: “Does the individual know that he is the makeweight that tips the scales?”.
- 2.
Some references claim the vaccines were sent worldwide while others maintain that people were sent to Europe for treatment.
- 3.
Vaccines in the Treatment of Disease, Page 239.
- 4.
“It has not escaped our notice that the specific pairing we have postulated immediately suggests a possible copying mechanism for the genetic material.” Molecular Structure of Nucleic Acids, Watson and Crick, Nature, No. 4356, April 25, 1953.
- 5.
Presumably aggregation of the viral particles/proteins would prevent the uniform application of the deactivating agent, formaldehyde.
- 6.
The CDC’s Morbidity and Mortality Weekly Report.
- 7.
- 8.
PCP is Pneumocystis pneumonia.
- 9.
- 10.
- 11.
a mammal of the deer family (Cervidae).
- 12.
- 13.
- 14.
SVP is subvisible particle.
- 15.
- 16.
- 17.
- 18.
“10. To characterize the types and amounts of subvisible particles in the drug product under stress conditions, at release, and throughout the dating period, and to propose an appropriate control strategy, based on the risk to product quality,” as per footnote [reference 15].
- 19.
Do not confuse with Affymetrix, now a Thermo Fisher Scientific company.
- 20.
type 258 (ST258), contains the carbapenemase gene.
- 21.
“During the past 10 years there has been a steady decline in the number of antibiotics submitted for approval to the FDA, with only 2 new antibiotics approved in the past 2 years, and those approved have been analogs of previously approved classes of antibiotics.” Cross.
References
Zhou H, Vong S, Liu K, Li Y, Mu D, Wang L, et al. Human Rabies in China, 1960–2014: a descriptive epidemiological study. PLoS Negl Trop Dis. 2016;10(8):e0004874.
Rubin BA. A note on the development of the bifurcated needle for smallpox vaccination. WHO Chron. 1980;34:180–1.
Baxby D. Smallpox vaccination techniques; from knives and forks to needles and pins. Vaccine. 2002;20:2140–9.
Pattanayak S, et al. Comparative studies of smallpox vaccination by the bifurcated needle and rotary lancet techniques. Bull World Health Organ. 1970;42:305–10.
Verran J, Reyes XA. Emerging infectious literatures and the zombie condition. Emerg Infect Dis. 2018;24(9):1774–8. www.cdc.gov/eid.
Lacy BE, Rosemore J. Helicobacter pylori: ulcers and more: the beginning of an era. J Nutr. 2001;131(10):2789S–93S.
Correa P. Helicobacter pylori and gastric carcinogenesis. Am J Surg Pathol. 1995;19:S37–43.
Blaser MJ, et al. Infection with Helicobacter pylori strains possessing cagA is associated with an increased risk of developing adenocarcinoma of the stomach. Cancer Res. 1995;55:2111–5.
Meurman JH, Sanz M, Janket SJ. Oral health, atherosclerosis, and cardiovascular disease. Crit Rev Oral Biol Med. 2004;15(6):403–13.
McLaughlin-Drubin ME, Munger K. Viruses associated with human cancer. Biochim Biophys Acta. 2008;1782(3):127–50.
Hajj J, Blaine N, Salavaci J, Jacoby D. The “Centrality of Sepsis”: a review on incidence, mortality, and cost of care. Healthcare. 2018;6:90. https://doi.org/10.3390/healthcare6030090.
Hillman J. Chapter 1, Senex and puer: an aspect of the historical and psychological present. In: Senex and puer. Putnam: Spring Publications; 2005.
Lederle Antitoxin Laboratories. Modern biologic therapeusis: a concise and practical treatise on biologic products for the use of practitioners in the modern application of immunology to therapeutics. New York: Medical Department; 1915.
Smith KA. Louis Pasteur, the father of immunology? Front Immunol. 2012;3:Article 68.
McGettigan JP. Experimental rabies vaccines for humans. Expert Rev Vaccines. 2010;9:1177–86.
Pasquale D, et al. Vaccine Adjuvants: from 1920 to 2015 and Beyond. Vaccines. 2015;3:320–43. https://doi.org/10.3390/vaccines3020320.
Jo Macfarlane for The Mail on Sunday. New thalidomide’ scandal over 1960s pregnancy test pill: damning new evidence exposes scale of alleged cover-up of Primodos super-strength hormone tablets, prescribed by GPs, PUBLISHED: 18:05 EST, 18 Mar 2017. 2017. Accessed online 9 Mar 2018. http://www.dailymail.co.uk/health/article-4327024/New-thalidomide-scandal-1960s-pregnancy-test-pill.html#ixzz59Gr2vm6W.
Templeton JS. Letter: septic abortion and the dalkon shield. British Med Journal. 1974;2(5919):612.
Youngdahl K. Early uses of diphtheria antitoxin in the United States. 2010. https://www.historyofvaccines.org/content/blog/early-uses-diphtheria-antitoxin-united-states. Accessed 4 July 2018.
Frankel AE, et al. Characterization of diphtheria fusion proteins targeted to the human interleukin-3 receptor. Protein Eng Des Sel. 2000;13(8):575–81.
Baldo B. Safety of biologics therapy. Cham: Springer International Publishing; 2017.
Spiess K, et al. Rationally designed chemokine-based toxin targeting the viral G protein-coupled receptor US28 potently inhibits cytomegalovirus infection in vivo. PNAS. 2015. www.pnas.org/cgi/doi/10.1073/pnas.1509392112.
Crunkhorn S. Infectious disease: fusion toxin protein inhibits CMV infection. Nat Rev Drug Discov. 2015;14:528.
FDA, Science and the Regulation of Biological Products. https://www.fda.gov/AboutFDA/WhatWeDo/History/ProductRegulation/100YearsofBiologicsRegulation/ucm070022.htm.
Nathanson N, Langmuir AD. The cutter incident poliomyelitis following formaldehyde-inactivated poliovirus vaccination in the United States during the spring of 1955: I. BACKGROUND. Am J Epidemiol. 1963;78(1):16–28.
Baicus A, History of polio vaccination. World J Virol. 2012;1(4):108–14. https://doi.org/10.5501/wjv.v1.i4.108.
Offit PA. The cutter incident: how America’s first polio vaccine led to the growing vaccine crisis. New Haven: Yale University Press; 2007.
Offit PA. Why are pharmaceutical companies gradually abandoning vaccines? congress has the power to protect vaccines, a product that is vital to the health of the United States and the rest of the world. Health Aff. 2005;24(3):622. The Vaccine Enterprise.
Epidemiologic Notes and Reports. Pneumocystis pneumonia—Los Angeles. In the period October 1980–May 1981, 5 young men, all active homosexuals, were treated for biopsy-confirmed Pneumocystis carinii pneumonia at 3 different hospitals in Los Angeles, California. Two of the patients died. All 5 patients had laboratory-confirmed previous or current cytomegalovirus (CMV) infection and candidal mucosal infection. Case reports of these patients follow. https://www.cdc.gov/mmwr/preview/mmwrhtml/june_5.htm.
Prusiner SB. Novel proteinaceous infectious particles cause scrapie. Science. 1982;216:136–44.
Bosque PJ, Tyler KL. 181 – Prions and Prion Diseases of the Central Nervous System (Transmissible Neurodegenerative Diseases). In: Bennett JE, Dolin R, Blaser MJ, editors. Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases, vol. 2. 8th ed; 2015. p. 2142–2153.e4.
Watts JC, Balachandran A, Westaway D. The expanding universe of prion diseases. PLoS Pathog. 2006;2(3):e26.
Will RG, Kimberlin RH. Creutzfeldt-Jakob disease and the risk from blood or blood products. Vox Sanguinis (Basel). 1998;75(3):178–80.
Llewelyn CA, Hewitt PE, et al. Possible transmission of variant Creutzfeldt Jakob disease by blood transfusion. Lancet. 2004;363(9407):417–21.
Peden AH, Head MW, et al. Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient. Lancet. 2004;364(9433):527–9.
U.K. Health Protection Agency. New case of transfusion-associated vCJD. Commun Dis Resp CDR Wkly. 2006;16:serial online.
Hewitt PE, Llewelyn CA, et al. Creutzfeldt-Jakob disease and blood transfusion: results of the UK Transfusion Medicine Epidemiological Review study. Vox Sang. 2006;91(3):221–30.
Amendment to “Revised Preventive Measures to Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease and Variant Creutzfeldt-Jakob Disease by Blood and Blood Products; Guidance for Industry” Draft Guidance for Industry. U.S. Department of Health and Human Services Food and Drug Administration Center for Biologics Evaluation and Research. 2017.
Bourne DC. Chronic wasting disease of cervids. Small Rumin Res. 2015;128:72–8.
Fatal degenerative neurologic illnesses in men who participated in wild game feasts – Wisconsin,2002. Morb Mortal Wkly Rep. 2003;52(07):125–7.
Goni F, et al. Mucosal immunization with an attenuated Salmonella vaccine partially protects white-tailed deer from chronic wasting disease. Vaccine. 2015;33:726–33.
Chung E, et al. Styryl-based and tricyclic compounds as potential anti-prion agents. PLoS One. 2011;6(9):e24844.
Wisniewski T, Goñi F. Immunomodulation for prion and prion-related diseases. Expert Rev Vaccines. 2010;9(12):1441–52.
Transfer of Therapeutic Products to the Center for Drug Evaluation and Research (CDER). https://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CBER/ucm133463.htm.
Information on CBER Restructuring. https://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CBER/ucm525907.htm.
CDER Offices and Divisions. https://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm075128.htm.
Timmis R. The biologics price competition and innovation act: potential problems in the biologic-drug regulatory scheme. Northwestern J Technol Intellect Prop. London, UK, 2015;215:Article 6.
European Medicine Agency. Guideline on similar biological medicinal products. European Medicine Agency, London, UK; 2014.
European Medicines Agency. CHMP/437/04 Rev. 1 Committee for Medicinal Products for Human Use (CHMP). Guideline on similar biological medicinal products. 2014.
Gámez-Belmonte R, et al. Biosimilars: concepts and controversies. Pharmacol Res. 2018;133:251–64.
Scavone C, et al. Strengths, weaknesses and future challenges of biosimilars’ development. An opinion on how to improve the knowledge and use of biosimilars in clinical practice. Pharmacol Res. 2017;126:138–42.
Nowgrodzki A. How can the U.S. catch up on biosimilars? Medcity News. 2018. Accessed 20 Apr 2018. https://medcitynews.com/2018/02/can-u-s-catch-biosimilars/.
Kent R, Biase D. Disruption and maturity: the next phase of biologics, QuintilesIMSTM™. 2018. https://www.iqvia.com/-/media/iqvia/pdfs/nemea/uk/disruption_and_maturity_the_next_phase_of_biologics.pdf?_=1518214264988. White paper. Accessed 20 Apr 2018.
Moorkens et al. Policies for biosimilar uptake in Europe: an overview. PLoS One. 2017;12(12):e0190147.
Fda’s Human Drug Compounding Progress Report. Three years after enactment of the drug quality and security act, FDA. 2017.
Paulson B. Uncertainties in subvisible particulates need to be understood, FDA tells biotech CMC Strategy Forum. 2011.
International pharmaceutical quality; 2(2), 11 Feb 2011. https://www.ipqpubs.com/.
Greb E. Pharmaceutical technology. PharmTech.com. 2011. Accessed Mar 2018.
Carpenter JF, et al. Overlooking subvisible particles in therapeutic protein products: gaps that may compromise product quality. J Pharm Sci. 2009;98(4):1201–5.
Singh SK et al. An industry perspective on the monitoring of subvisible particles as a quality attribute for protein therapeutics. J Pharm Sci. 2010;99(8):3302–21. https://doi.org/10.1002/jps.22097.
Kotarek J, et al. Subvisible particle content, formulation, and dose of an erythropoietin peptide mimetic product are associated with severe adverse postmarketing events. J Pharm Sci. 2016;105(3):1023–7.
ECA Academy, Oct. 09, 2014. Commentary Regarding new USP Chapters <787> and <1787> for Particulate Matter Guidance.
Tisoncik JR, et al. Into the eye of the cytokine storm. Microbiol Mol Biol Rev. 2012;76(1):16–32.
Attarwala H. TGN1412: from discovery to disaster. J Young Pharm. 2010;2(3):332–6.
Investigations into Adverse Incidents during Clinical Trials of TGN1412. London: Medicines and Healthcare Pproducts Regulatory Agency (MHRA). (2006). Accessed 11 Aug 2006.
American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med. 1992;20(6):864–74.
Hunig T. The rise and fall of the CD28 superagonist TGN1412 and its return as TAB08: a personal account. FEBS J. 2016;283:3325–34.
Suntharalingam G, Perry MR, Ward S, Brett SJ, Castello-Cortes aA, Brunner MD, Panoskaltsis N. Cytokine storm in a phase 1 trial of the antiCD28 monoclonal antibody TGN1412. New England J Med. 2006;355:1018–28.
GWC D. Expert Scientific Group on Phase One Clinical Trials Final Report. Norwich: Stationary Office; 2006.
Hunig T. The storm has cleared: lessons from the CD28 superagonist TGN1412. Nat Rev Immunol. 2012;12:317–8.
Satlin MJ, Chen L, Patel G, Gomez-Simmonds A, Weston G, Kim AC, Seo SK, Rosenthal ME, Sperber SJ, Jenkins SG, Hamula CL, Uhlemann A-C, Levi MH, Fries BC, Tang Y-W, Juretschko S, Rojtman AD, Hong T, Mathema B, Jacobs MR, Walsh TJ, Bonomo RA, Kreiswirth BN. Multicenter clinical and molecular epidemiological analysis of bacteremia due to Carbapenem-Resistant Enterobacteriaceae (CRE) in the CRE epicenter of the United States. Antimicrob Agents Chemother. 2017;61:e02349-16. https://doi.org/10.1128/AAC.02349-16.
Cross AS. Anti-endotoxin vaccines back to the future. Virulence. 2014;5(1):219–25.
Jeannot K, Bolard A, Plésiat P. Resistance to polymyxins in Gram-negative organisms. Int J Antimicrob Agents. 2017;49:526–35.
Motley MP, Fries BC. A new take on an old remedy: generating antibodies against multidrug-resistant Gram-negative bacteria in a postantibiotic world. mSphere. 2017;2(5):e00397-17.
Gao R, et al. Dissemination and mechanism for the MCR-1 colistin resistance. PLoS Pathog. 2016;12(11):e1005957.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Williams, K.L. (2019). Origins and Evolution of Drug Regulation. In: Williams, K. (eds) Endotoxin Detection and Control in Pharma, Limulus, and Mammalian Systems. Springer, Cham. https://doi.org/10.1007/978-3-030-17148-3_2
Download citation
DOI: https://doi.org/10.1007/978-3-030-17148-3_2
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-17147-6
Online ISBN: 978-3-030-17148-3
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)